Traders should monitor the integration of Rendiatech, progress on the Vivian pediatric solution, and whether Q4's commercial momentum sustains into 2026. The $5M capital raise provides near-term runway, but profitability remains a challenge.
Price Chart
Executive Summary
Nuwellis reported mixed Q4 and full-year 2025 results: Q4 revenue rose 4% YoY to $2.4 million with strong gross margin expansion to 68.2%, but full-year revenue declined 5% to $8.3 million. The company incurred a $17.5 million net loss, driven by a $6.4 million non-cash warrant expense. It also announced a $5 million private placement, a new CFO, and an acquisition of Rendiatech to expand its cardiorenal portfolio.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $2.4 million, up 4% YoY and 9% sequentially
- Q4 gross margin improved to 68.2% from 58.4% in prior year
- Full-year 2025 revenue: $8.3 million, down 5% from 2024
- Net loss attributable to common shareholders: $17.5 million for the year
- Closed $5.0 million private placement in January 2026
- Appointed new CFO and announced acquisition of Rendiatech
Financial Impact
Revenue declined 5% for the year despite Q4 improvement; gross margin expanded significantly; $6.4M of the $17.5M net loss was non-cash warrant valuation
Risk Factors
- Full-year revenue declined despite Q4 improvement
- High net loss driven by recurring non-cash expenses and operating deficits
- Low cash balance of $1.2 million at year-end, though bolstered by $5M January raise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252779 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $0.3221 | awaiting T+20 | — | $3.07 (+851.69%) |
Sep 18, 2026 5w ago | SC 13G/A | $0.8700 $0.5600 | ▼ −35.63% | ▼ −34.72% | $3.07 (+252.34%) |
Sep 17, 2026 5w ago | Press Release | $1.09 $0.5532 | ▲ +49.25% | ▲ +50.45% | $3.07 (−181.23%) |
Aug 27, 2026 8w ago | EFFECT | $0.9900 $0.7915 | ▲ +20.05% | ▲ +19.95% | $3.07 (−209.64%) |
Aug 25, 2026 9w ago | 8-K | $1.01 $0.8700 | ▼ −13.86% | ▼ −15.06% | $3.07 (+203.50%) |
Aug 13, 2026 10w ago | Press Release | $1.30 $0.7740 | ▲ +40.46% | ▲ +38.71% | $3.07 (−135.80%) |
Aug 3, 2026 12w ago | 424B5 | $14.49 $7.13 | ▲ +50.78% | ▲ +52.01% | $3.07 (+78.84%) |
Jul 31, 2026 12w ago | Press Release | $1.74 $0.8889 | ▲ +48.91% | ▲ +51.90% | $3.07 (−76.17%) |
Jun 16, 2026 19w ago | Press Release | $0.1350 $0.0840 | ▼ −37.78% | ▼ −37.83% | $3.07 (+2170.67%) |
Jun 10, 2026 19w ago | 8-K | $0.1520 $0.0869 | ▲ +42.86% | ▲ +46.93% | $3.07 (−1916.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers